]>
IRCT20190122042450N4 IRCT 2020-04-16 Iran University of Medical Sciences The effect of hydroxychloroquine to prevent coronavirus disease Prevention of COVID-19 disease after contact with an infected patient with coronavirus after taking hydroxychloroquine in the community 2020-04-20 anticipated 1000 Complete https://irct.ir/trial/47090 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: Randomization is done using random block method with variable block size. In this method, a number is randomly selected from the numbers 2, 4, 6, and 8. Then, according to the size of the selected block, a random combination of 2 studied treatments is selected. This process is repeated to the extent that a sequence of 1000 of 1 and 2 treatments is created, provided that the number of each of the two treatments is 500. At the time of performance, for each patient, by referring to this list, it is decided which of the two treatments to be assigned to him. 3 Covid-19. Intervention 1: Intervention group: hydroxychloroquine Ruzdarou 200mg; This group take 2 hydroxychloroquine tablet (400 mg) for the first day and From the second day, take one tablet (200 mg) daily for two weeks. Intervention 2: Control group: Domestic quarantine for 14 days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is unclarifed
public Mohammad Ebrahim Khamseh
Firoozeh Alley, Vali-asr Sq, Tehran, Iran
Tehran Iran (Islamic Republic of) 1593716615 +98 21 8894 5171 khamseh.m@iums.ac.ir The Institute of Endocrinology and Metabolism Research and Training Center scientific Mohammad Ebrahim Khamseh
Firoozeh Alley, Vali-asr Sq, Tehran, Iran
Tehran Iran (Islamic Republic of) 1593716615 +98 21 8603 6064 khamseh.m@iums.ac.ir The Institute of Endocrinology and Metabolism Research and Training Center Iran (Islamic Republic of) Clinical symptoms including: Fever Shortness of breath Cough Positive Covide test Typical symptoms on a CT scan 40 years no limit Both Hypersensitivity reaction to Hydroxychloroquine Already taking Chloroquine or Hydroxychloroquine Cardiac Arrhythmia Already taking drugs that prolong QT Decreased renal function in stages 4 and 5.(GFR <30) The history of enzymatic disorders caused by some drugs that result in red blood cell lysis (G6PD). The history of Retinopathy Pregnancy U07.1 COVID-19, Virus Identified Prevention Prevention Intervention group: hydroxychloroquine Ruzdarou 200mg; This group take 2 hydroxychloroquine tablet (400 mg) for the first day and From the second day, take one tablet (200 mg) daily for two weeks. Control group: Domestic quarantine for 14 days Reduction of incubation time. Timepoint: Daily for 14 days. Method of measurement: Participants' clinical status. Reducing the incidence of Symptomatic respiratory disease. Timepoint: 14 days after taking hydroxychloroquine. Method of measurement: CT-scan test. Iran University of Medical Sciences Approved 2020-04-11 Ethics committee of Iran University of Medical Sciences Hemmat Highway. Next to Milad Tower Tehran Tehran Iran (Islamic Republic of)